Critical Factors For New Therapy for Gynecologic Cancer – StraightForward Advice
Posted by admin | Uncategorized | Posted on January 22nd, 2012
Patients who have gynecologic cancer have fresh anticipation in a innovative technology now made available at the Seidman Cancer Center at University Hospitals Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.
Undertaken swiftly following surgical procedure, HIPEC supplies heated chemotherapy through a ‘hot bath’ into the abdominal cavity, where it can penetrate diseased tissue directly. Subsequently after the physician takes away as much visible cancer as practical, a heated, a sterilized chemotherapy solution is distributed within the mid-section through a technically advanced perfusion system to eliminate the surviving cancer cells.
“This is a new and potentially revolutionary way of treating women with gynecologic cancers, which tend to be quite responsive to chemotherapy,” says Dr. DeBernardo, gynecologic oncologist at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “Our preliminary data and experience has been overwhelmingly positive and the therapy has been well-tolerated and effective. HIPEC promises to extend lives in a meaningful way.”
HIPEC has been used for years for public health care in patients with colon, pseudomyxomas, malignant mesothelioma and appendiceal cancer, varieties of cancer that generally speaking are usually not receptive to chemotherapy, yet it’s now looked at as an encouraging new treatment method for gynecologic malignancy.